Ganymed Robotics extended its Series B with an additional close of €15 million (~USD $15.9 million), bringing the total Series B amount to €36 million. The initial Series B close of €21 million was announced in July 2022.
The combined funds will be used to complete development of Ganymed Robotics’ surgical robotic assistant for knee arthroplasty (TKA), accelerate regulatory and market access activities, and diversify the innovation product pipeline.
Ganymed Robotics seeks to democratize access to quality care in orthopedics and allow all such patients throughout the world, to benefit from high-quality care. It has developed a proprietary technology platform built around contactless localization of the bones and human-machine collaborative movement. The first application is a co-manipulated surgical robotic assistant for TKA.
Ganymed’s device aims to improve both patient outcome and surgeon experience in a value-based care environment. After TKA, Ganymed is planning to expand its technology platform to address other market needs.
“Welcoming such highly valuable investors a few months after an oversubscribed Series B first close, puts us in an extremely solid position amid a worldwide financing crunch for start-ups. We now have the resources and expertise to bring our unique patented technology to market, with the aim to become standard of care for joint replacement,” says Sophie Cahen, CEO and co-founder of Ganymed Robotics.
Ganymed Robotics extended its Series B with an additional close of €15 million (~USD $15.9 million), bringing the total Series B amount to €36 million. The initial Series B close of €21 million was announced in July 2022.
The combined funds will be used to complete development of Ganymed Robotics’ surgical robotic assistant for knee...
Ganymed Robotics extended its Series B with an additional close of €15 million (~USD $15.9 million), bringing the total Series B amount to €36 million. The initial Series B close of €21 million was announced in July 2022.
The combined funds will be used to complete development of Ganymed Robotics’ surgical robotic assistant for knee arthroplasty (TKA), accelerate regulatory and market access activities, and diversify the innovation product pipeline.
Ganymed Robotics seeks to democratize access to quality care in orthopedics and allow all such patients throughout the world, to benefit from high-quality care. It has developed a proprietary technology platform built around contactless localization of the bones and human-machine collaborative movement. The first application is a co-manipulated surgical robotic assistant for TKA.
Ganymed’s device aims to improve both patient outcome and surgeon experience in a value-based care environment. After TKA, Ganymed is planning to expand its technology platform to address other market needs.
“Welcoming such highly valuable investors a few months after an oversubscribed Series B first close, puts us in an extremely solid position amid a worldwide financing crunch for start-ups. We now have the resources and expertise to bring our unique patented technology to market, with the aim to become standard of care for joint replacement,” says Sophie Cahen, CEO and co-founder of Ganymed Robotics.
Copy to clipboard 
